Navigation Links
Organovo and Methuselah Foundation Announce Funding of Bioprinting Research at Research Institutions

SAN DIEGO, July 24, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, and Methuselah Foundation, a public charity incentivizing innovation in regenerative medicine, today announced that Methuselah Foundation has initiated a campaign in which it will fund research at major research institutions using Organovo's proprietary NovoGen Bioprinting technology. 

The program will feature grants of research funding from the non-profit Methuselah Foundation to major academic research centers engaged in cutting edge biomedical research.  Eligible institutions will include public and private research universities and private non-profit research institutes.  Under the program, Methuselah Foundation will divide a donation of at least $500,000 in direct funding for research projects across several institutions. 

Methuselah Foundation Chief Executive Officer David Gobel commented, "Our donors expect us to drive beneficially disruptive medical technology forward. Their funding support is doing exactly that by placing Organovo's breakthrough 3D bioprinting technology in the hands of the brightest scientists that tissue engineering centers of excellence have to offer."

"Organovo's technology has broad potential application in the life sciences," said Keith Murphy, chief executive officer of Organovo.  "The opportunity to allow those working towards significant breakthroughs in organ bioprinting to use the NovoGen MMX bioprinter is exciting, and we're happy to be able to establish this joint effort with Methuselah Foundation to enable greater access to Organovo's powerful platform."

The funding will go to cover budgeted bioprinter costs or other aspects of project execution.  Organovo will participate in selection of the best opportunities to fund among institutions that request such funding.  The initial funding is currently available and will begin as soon as candidate institutions are selected.  An expected outcome from the program is a greater set of preliminary results to justify the granting of additional government research grants in the 3D bioprinting space.  Organovo and Methuselah are confident that the program can become a springboard for much broader productive use of bioprinting in a number of areas of biological research.

About Organovo Holdings, Inc. 
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, our technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo listed on the New York Stock Exchange MKT on July 11, 2013.  The company is dedicated to changing the shape of medical research and practice. Learn more at

About Methuselah Foundation 

The Methuselah Foundation is a non-profit medical charity working to create a world where 90 year olds can have the health profile of 50 year olds, by 2028. By opportunistically leveraging resources, enabling partnerships, and awarding prizes and grants, we accelerate disruptive developments in biomedical engineering that will eradicate needless suffering and extend healthy human life. For more information please visit:

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our transition report on Form 10-KT filed with the SEC on May 24, 2013.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo Reports Fiscal 2013 Financial Results
2. Organovo Holdings, Inc. Announces Change of Fiscal Year
3. Organovo Reports 2012 Financial Results
4. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
5. Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
6. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
7. Organovo Reports Q2 2012 Financial Results, Provides Business Update
8. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at
9. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
10. Organovo Holdings Appoints James T. Glover to Board of Directors
11. National Association of Specialty Pharmacy (NASP) Partners with the Patient Access Network (PAN) Foundation to Host Charity Golf Outing at Upcoming Meeting
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):